A rapid screening method to evaluate the impact of nanoparticles on macrophages

Abstract

Nanotechnology is an emerging and highly promising field to develop new approaches for biomedical applications. There is however at present an unmet need for a rapid and universal method to screen nanoparticles (NP) for immunocompatibility at early stages of their development. Indeed, although many types of highly diverse NP are currently under investigation, their interaction with immune cells remains fairly unpredictable. Macrophages which are professional phagocytic cells are believed to be among the first cell types that take up NP, mediating inflammation and thus immunological responses. The present work describes a highly reproducible screening method to study the NP interaction with macrophages. Three essential questions are answered in parallel, in a single multiwell plate: Are the NP taken up by macrophages? Do the NP cause macrophage cell death? Do the NP induce inflammatory reactions? This assay is proposed as a standardized screening protocol to obtain a rapid overview of the impact of different types of NP on macrophages. Due to high reproducibility, this method also allows quality control assessment for such aspects as immune-activating contaminants and batch-to-batch variability.

<p>Silver-Containing Titanium Dioxide Nanocapsules for Combating Multidrug-Resistant Bacteria</p>

“…For biomedical applications, reproducibility of nanoparticle synthesis is essential, as moderate differences in physicochemical properties can lead to changes in biocompatibility, in particular with respect to immune cells. 45 In a straightforward and highly reproducible synthesis, TiO 2 NC with tunable AgNP content and a diameter of 200 ± 10 nm were obtained at low temperature in their amorphous state. 46 Polymeric capping agents, like remaining PS and PVP, may be responsible for the decrease of the dissolution rate of AgNPs.…”

Engineered hybrid spider silk particles as delivery system for peptide vaccines

“…Bone marrow-derived dendritic cells (BMDC) and single-cell suspensions of primary splenocytes were prepared as described [40], plated in flat-bottom 96-well plates (5x10 4 cells/well) and exposed to spider silk particles at a working concentration of 50 mg/ ml (¼ 1 mg OVA peptide/ml) except for cytotoxicity testing (500 mg/ ml). At 500 mg/ml, particles did not interfere with ELISA or flow cytometry reading [41]. OVA peptide (1 mg/ml) was used as control.…”

Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems

“…A safe entry of the cells, therefore, becomes a crucial factor to be considered for the effectiveness of nanomedicine [176]. Since macrophages are considered to be the first cells that take up nanoparticles, assessing the impact of nanocarriers on macrophages can be used to evaluate their immunocompatibility [178]. Mottas et al have recently developed a rapid screening method to evaluate the impact of nanoparticles on macrophages, providing a new approach to assess cytotoxicity as well as quality control of nanoparticles [178].…”